Risperdal Gynecomastia Suit Dismissed; Warning Adequate, No Causation Testimony

Mealey's (July 11, 2018, 10:03 AM EDT) -- BROOKLYN, N.Y. — A New York federal judge on June 29 granted summary judgment in a Risperdal gynecomastia case, finding that the drug’s various labels warned of the risk and that the plaintiff presented no specific causation testimony (Tyrieke Chandler v. Janssen Pharmaceuticals, Inc., et al., No. 15-3106, E.D. N.Y., 2018 U.S. Dist. LEXIS 109346)....

Attached Documents

Related Sections